Contemporary rends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States


Allard C. B. , Gelpi-Hammerschmidt F., Harshman L. C. , Choueiri T. K. , Faiena I., Modi P., ...Daha Fazla

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, cilt.33, sa.11, 2015 (SCI İndekslerine Giren Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Konu: 11
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.urolonc.2015.06.014
  • Dergi Adı: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Özet

Background: Targeted therapies (TTs) have revolutionized metastatic renal cell carcinoma (mRCC) treatment in the past decade, largely replacing immunotherapy including high-dose interleukin-2 (HD IL-2) therapy. We evaluated trends in HD IL-2 use for mRCC in the IT era.